1. Home
  2. COCP vs SCNX Comparison

COCP vs SCNX Comparison

Compare COCP & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

N/A

Current Price

$1.01

Market Cap

19.2M

Sector

Health Care

ML Signal

N/A

Logo Scienture Holdings Inc.

SCNX

Scienture Holdings Inc.

N/A

Current Price

$3.21

Market Cap

16.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
COCP
SCNX
Founded
N/A
2010
Country
United States
United States
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Pharmaceuticals
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.2M
16.2M
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
COCP
SCNX
Price
$1.01
$3.21
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $8.00
N/A
AVG Volume (30 Days)
33.0K
★ 49.6K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 54.65
N/A
EPS
N/A
★ N/A
Revenue
★ $12,712,091.00
$3,831,778.00
Revenue This Year
N/A
$743.36
Revenue Next Year
N/A
$325.03
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 30.72
52 Week Low
$0.76
$2.64
52 Week High
$2.03
$106.25

Technical Indicators

Market Signals
Indicator
COCP
SCNX
Relative Strength Index (RSI) 43.22 47.07
Support Level $0.98 $2.64
Resistance Level $1.10 $10.60
Average True Range (ATR) 0.06 0.32
MACD 0.00 -0.02
Stochastic Oscillator 42.57 49.61

Price Performance

Historical Comparison
COCP
SCNX

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

About SCNX Scienture Holdings Inc.

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.

Share on Social Networks: